MONROVIA, Calif., March 19, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of business highlights. "We are very pleased that Xencor now has five clinical programs ongoing, internally and with partners, employing our XmAb® antibody engineering technology with a sixth program starting soon," said Bassil Dahiyat, Ph.D., President and CEO of Xencor. "Our technology enables subtle changes to the natural...
↧